From charcot to lou gehrig: deciphering selective motor neuron death in als

Nature Reviews Neuroscience

Volumn 2, Issue 11, 2001, Pages 806-819

  Cleveland, Don W ^a   Rothstein, Jeffrey D ^b  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; COPPER; CPP32 PROTEIN; ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; NEUROFILAMENT PROTEIN; SUPEROXIDE DISMUTASE; SUPEROXIDE DISMUTASE 1; VASCULOTROPIN; ZINC;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL; ASTROCYTE; BIOLOGICAL MODEL; CELL DEATH; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; HUMAN; METABOLISM; MOTONEURON; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; REVIEW;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL; ASTROCYTES; CASPASES; CELL DEATH; COPPER; ENDOTHELIAL GROWTH FACTORS; HUMAN; LYMPHOKINES; MODELS, MOLECULAR; MODELS, NEUROLOGICAL; MOTOR NEURONS; NEUROFILAMENT PROTEINS; OXIDATION-REDUCTION; PROTEIN STRUCTURE, TERTIARY; SUPEROXIDE DISMUTASE; ZINC;

EID: 0035516124     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/35097565     Document Type: Article

References (157)

1. Charcot, J. M. & Joffory, A. Deux cas d'atrophie musculaire progressive avec lesions de la substance grise et des faisceaux antero-lateraux de la moelle epiniere. Arch. Physiol. Weurol. Pathol. 2, 744-754 (1869).
2. Yoshida, S., Mulder, D. W., Kurland, L. T., Chu, C. P & Okazaki, H. Follow-up study on amyotrophic lateral sclerosis in Rochester, Minn., 1925 through 1984. Weuroepidemiology 5, 61-70 (1986).
3. Rosen, D. R. et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Wature 362, 59-62 (1993).
4. Hirano, A., Donnenfeld, H., Sasaki, S. & Nakano, I. Fine structural observations of neurofilamentous changes in amyotrophic lateral sclerosis. J. Weuropathol. Exp. Weurol. 43, 461-470 (1984).
5. Hirano, A. et al. Fine structural study of neurofibrillary changes in a family with amyotrophic lateral sclerosis. J. Weuropathol. Exp. Weurol. 43, 471-480 (1984).
6. Bruijn, L. I. et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 281, 1851-1854 (1998).
7. Mulder, D. W., Kurland, L. T., Offord, K. P. & Beard, C. M. Familial adult motor neuron disease: amyotrophic lateral sclerosis. Neurology 36, 511-517 (1986).
8. Longo, V. D., Gralla, E. B. & Valentine, J. S. Superoxide dismutase activity is essential for stationary phase survival in Saccharomyces cerevisiae. Mitochondrial production of toxic oxygen species in vivo. J. Biol. Chem. 271, 12275-12280 (1996).
9. Andersen, P M., Morita, M. & Brown, R. H. Jr. in Amyotrophic Lateral Sclerosis (eds Brown, R. H., Meininger, V & Swash, M.) 223-250 (Martin Dunitz, London, 2000).
10. Gaudette, M., Hirano, M. & Siddique, T. Current status of SOD1 mutations in familial amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Weuron Disord. 1, 83-89 (2000).
11. Andersen, P. M. Genetics of sporadic ALS. Amyotroph. Lateral Scler. Other Motor Weuron Disord. 2, S37-S41 (2001).
12. Andersen, P M. et al. Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase. Wature Genet. 10, 61-66 (1995).
13. Andersen, P M. et al. Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients. Brain 119, 1153-1172 (1996).
14. Deng, H. X. et al. Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase. Science 261, 1047-1051 (1993).
15. Orrell, R., De Belleroche, J., Marklund, S., Bowe, F. & Hallewell, R. A novel SOD mutant and ALS. Wature 374, 504-505 (1995).
16. Gurney, M. E. et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264, 1772-1775 (1994).
17. Wong, P C. et al. An adverse property of a familial ALS- linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Weuron 14, 1105-1116 (1995).
18. Ripps, M. E., Huntley, G. W., Hof, P R., Morrison, J. H. & Gordon, J. W. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc. WatlAcad. Sci. USA 92, 689-693 (1995).
19. Bruijn, L. I. et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Weuron 18, 327-338 (1997).
20. Reaume, A. G. et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Wature Genet. 13, 43-47 (1996).
21. Borchelt, D. R. et al. Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. Proc. Watl Acad. Sci. USA 91, 8292-8296 (1994).
22. Bowling, A. C. et al. Superoxide dismutase concentration and activity in familial amyotrophic lateral sclerosis. J. Weurochem. 64, 2366-2369 (1995).
23. Cleveland, D. W., Laing, N., Hurse, P. V & Brown, R. H. Jr. Toxic mutants in Charcot's sclerosis. Wature 378, 342-343 (1995).
24. Kostic, V, Jackson-Lewis, V, De Bilbao, F., Dubois- Dauphin, M. & Przedborski, S. Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 277, 559-562 (1997).
25. Vukosavic, S. et al. Delaying caspase activation by Bcl-2: a clue to disease retardation in a transgenic mouse model of amyotrophic lateral sclerosis. J. Weurosci. 20, 9119-9125 (2000).
26. Li, M. et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 288, 335-339 (2000).
27. Pasinelli, P., Houseweart, M. K., Brown, R. H. Jr & Cleveland, D. W. Caspase-1 and -3 are sequentially activated in motor neuron death in Cu, Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis. Proc. Watl Acad. Sci. USA 97, 13901-13906 (2000).
28. Guegan, C., Vila, M., Rosoklija, G., Hays, A. P & Przedborski, S. Recruitment of the mitochondrial- dependent apoptotic pathway in amyotrophic lateral sclerosis. J. Weurosci. 21, 6569-6576 (2001).
29. Corson, L. B., Strain, J. J., Culotta, V C. & Cleveland, D. W. Chaperone-facilitated copper binding is a property common to several classes of familial amyotrophic lateral sclerosis- linked superoxide dismutase mutants. Proc. Watl Acad. Sci. USA 95, 6361-6366 (1998).
30. Beckman, J. S., Carson, M., Smith, C. D. & Koppenol, W. H. ALS, SOD and peroxynitrite. Wature 364, 584 (1993).
31. Ferrante, R. J. et al. Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Ann. Weurol. 42, 326-334 (1997).
32. Bruijn, L. I. et al. Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant. Proc. Watl Acad. Sci. USA 94, 7606-7611 (1997).
33. Andrus, P K., Fleck, T J., Gurney, M. E. & Hall, E. D. Protein oxidative damage in a transgenic mouse model of familial amyotrophic lateral sclerosis. J. Weurochem. 71, 2041-2048 (1998).
34. Beal, M. F. et al. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann. Weurol. 42, 644-654 (1997).
35. Jaarsma, D. et al. Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates motoneuron disease in mice expressing a familial amyotrophic lateral sclerosis mutant SOD1. Weurobiol. Dis. 7, 623-643 (2000).
36. Wiedau-Pazos, M. et al. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science 271, 515-518 (1996).
37. 2. Proc. Watl Acad. Sci. USA 95, 6675-6680 (1998).
38. Hall, E. D., Andrus, P. K., Oostveen, J. A., Fleck, T J. & Gurney, M. E. Relationship of oxygen radical-induced lipid peroxidative damage to disease onset and progression in a transgenic model of familial ALS. J. Weurosci. Res. 53, 66-77 (1998).
39. Borchelt, D. R. et al. Superoxide dismutase 1 subunits with mutations linked to familial amyotrophic lateral sclerosis do not affect wild-type subunit function. J. Biol. Chem. 270, 3234-3238 (1995).
40. Crow, J. P, Sampson, J. B., Zhuang, Y, Thompson, J. A. & Beckman, J. S. Decreased zinc affinity of amyotrophic lateral sclerosis-associated superoxide dismutase mutants leads to enhanced catalysis of tyrosine nitration by peroxynitrite. J. Weurochem. 69, 1936-1944 (1997).
41. Estevez, A. G. et al. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science 286, 2498-2500 (1999).
42. Williamson, T. L. et al. Toxicity of ALS-linked SOD1 mutants. Science 288, 399-400 (2000).
43. Goto, J. J. et al. Loss of in vitro metal ion binding specificity in mutant copper-zinc superoxide dismutases associated with familial amyotrophic lateral sclerosis. J. Biol. Chem. 275, 1007-1014 (2000).
44. Facchinetti, F. et al. Lack of involvement of neuronal nitric oxide synthase in the pathogenesis of a transgenic mouse model of familial amyotrophic lateral sclerosis. Weuroscience 90, 1483-1492 (1999).
45. Doroudchi, M. M., Minotti, S., Figlewicz, D. A. & Durham, H. D. Nitrotyrosination contributes minimally to toxicity of mutant SOD1 associated with ALS. Weuroreport 12, 1239-1243 (2001).
46. Shaw, P J., Ince, P. G., Falkous, G. & Mantle, D. Oxidative damage to protein in sporadic motor neuron disease spinal cord. Ann. Weurol. 38, 691-695 (1995).
47. Bowling, A. C., Schulz, J. B., Brown, R. H. Jr & Beal, M. F. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J. Weurochem. 61, 2322-2325 (1993).
48. Dal Canto, M. C. & Gurney, M. E. Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. Am. J. Pathol. 145, 1271-1279 (1994).
49. Kong, J. & Xu, Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J. Weurosci. 18, 3241-3250 (1998).
50. Culotta, V. C. et al. The copper chaperone for superoxide dismutase. J. Biol. Chem. 272, 23469-23472 (1997).
51. Wong, P. C. et al. Copper chaperone for superoxide dismutase is essential to activate mammalian Cu/Zn superoxide dismutase. Proc. Watl Acad. Sci. USA 97, 2886-2891 (2000).
52. Ferrante, R. J. et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J. Weurochem. 69, 2064-2074 (1997).
53. Johnston, J. A., Dalton, M. J., Gurney, M. E. & Kopito, R. R. Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc. Watl Acad. Sci. USA 97, 12571-12576 (2000).
54. Mather, K. et al. Histochemical and immunocytochemical study of ubiquitinated neuronal inclusions in amyotrophic lateral sclerosis. Weuropathol.Appl. Weurobiol. 19, 141-145 (1993).
55. Leigh, P N. et al. Ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis. Morphology, distribution, and specificity. Brain 114, 775-788 (1991).
56. Leigh, P N. et al. Ubiquitin deposits in anterior horn cells in motor neurone disease. Weurosci. Lett. 93, 197-203 (1988).
57. Bruening, W. et al. Up-regulation of protein chaperones preserves viability of cells expressing toxic Cu/Zn- superoxide dismutase mutants associated with amyotrophic lateral sclerosis. J. Weurochem. 72, 693-699 (1999).
58. Durham, H. D., Roy, J., Dong, L. & Figlewicz, D. A. Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS. J. Weuropathol. Exp. Weurol. 56, 523-530 (1997).
59. Rothstein, J. D. et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Weuron 16, 675-686 (1996).
60. Gong, Y. H., Parsadanian, A. S., Andreeva, A., Snider, W. D. & Elliott, J. L. Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J. Weurosci. 20, 660-665 (2000).
61. Williamson, T. L. et al. Absence of neurofilaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis- linked superoxide dismutase 1 mutant. Proc. Watl Acad. Sci. USA 95, 9631-9636 (1998).
62. Couillard-Despres, S. et al. Protective effect of neurofilament heavy gene overexpression in motor neuron disease induced by mutant superoxide dismutase. Proc. Watl Acad. Sci. USA 95, 9626-9630 (1998).
63. Pramatarova, A., Laganiere, J., Roussel, J., Brisebois, K. & Rouleau, G. A. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J. Weurosci. 21, 3369-3374 (2001).
64. Carpenter, S. Proximal axonal enlargement in motor neuron disease. Weurology 18, 841-851 (1968).
65. Xu, Z., Cork, L. C., Griffin, J. W. & Cleveland, D. W. Increased expression of neurofilament subunit NF-L produces morphological alterations that resemble the pathology of human motor neuron disease. Cell 73, 23-33 (1993).
66. Cote, F., Collard, J. F. & Julien, J. P Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: a mouse model of amyotrophic lateral sclerosis. Cell 73, 35-46 (1993).
67. Couillard-Despres, S., Meier, J. & Julien, J. P. Extra axonal neurofilaments do not exacerbate disease caused by mutant Cu, Zn superoxide dismutase. Weurobiol. Dis. 7, 462-470 (2000).
68. Nguyen, M. D., Lariviere, R. C. & Julien, J. P. Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions. Weuron 30, 135-147 (2001).
69. Kong, J. & Xu, Z. Overexpression of neurofilament subunit NF-L and NF-H extends survival of a mouse model for amyotrophic lateral sclerosis. Weurosci. Lett. 281, 72-74 (2000).
70. Williamson, T L. & Cleveland, D. W. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Wature Weurosci. 2, 50-56 (1999).
71. Willard, M. & Simon, C. Modulations of neurofilament axonal transport during the development of rabbit retinal ganglion cells. Cell 35, 551-559 (1983).
72. Al-Chalabi, A. et al. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum. Mol. Genet. 8, 157-164 (1999).
73. Figlewicz, D. A. et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum. Mol. Genet. 3, 1757-1761 (1994).
74. Tomkins, J. et al. Novel insertion in the KSP region of the neurofilament heavy gene in amyotrophic lateral sclerosis (ALS). Weuroreport 9, 3967-3970 (1998).
75. De Jonghe, P. et al. Further evidence that neurofilament light chain gene mutations can cause Charcot-Marie-Tooth disease type 2E. Ann. Weurol. 49, 245-249 (2001).
76. Mersiyanova, I. V. et al. A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene. Am. J. Hum. Genet. 67, 37-46 (2000).
77. Xu, Z. et al. Subunit composition of neurofilaments specifies axonal diameter. J. Cell Biol. 133, 1061-1069 (1996).
78. Kawamura, Y. et al. Morphometric comparison of the vulnerability of peripheral motor and sensory neurons in amyotrophic lateral sclerosis. J. Weuropathol. Exp. Weurol. 40, 667-675 (1981).
79. Lee, M. K., Marszalek, J. R. & Cleveland, D. W. A mutant neurofilament subunit causes massive, selective motor neuron death: implications for the pathogenesis of human motor neuron disease. Weuron 13, 975-988 (1994).
80. Tanaka, K. et al. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 276, 1699-1702 (1997).
81. Rothstein, J. D. et al. Excitatory amino acids in amyotrophic lateral sclerosis: an update. Ann. Weurol. 30, 224-225 (1991).
82. Rothstein, J. D. et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann. Weurol. 28, 18-25 (1990).
83. Shaw, P J., Forrest, V, Ince, P. G., Richardson, J. P. & Wastell, H. J. CSF and plasma amino acid levels in motor neuron disease — elevation of CSF glutamate in a subset of patients. Weurodegeneration 4, 209-216 (1995).
84. Spreux-Varoquaux, O. et al. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis. A reapprasial using a new HPLC method with coulometric detection in a large cohort of patients. J. Weurol. Sci. (in the press).
85. Rothstein, J. D., Van Kammen, M., Levey, A. I., Martin, L. J. & Kuncl, R. W. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Weurol. 38, 73-84 (1995).
86. Lin, C. L. et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Weuron 20, 589-602 (1998).
87. Meyer, T. et al. The RNA of the glutamate transporter EAAT2 is variably spliced in amyotrophic lateral sclerosis and normal individuals. J. Weurol. Sci. 170, 45-50 (1999).
88. Honig, L. S., Chambliss, D. D., Bigio, E. H., Carroll, S. L. & Elliott, J. L. Glutamate transporter EAAT2 splice variants occur not only in ALS, but also in AD and controls. Weurology 55, 1082-1088 (2000).
89. Spencer, P. S. et al. Lathyrism: evidence for the role of the neuroexcitatory amino acid BOAA. Lancet 2, 1066-1067 (1986).
90. Spencer, P. S. et al. Guam ALS-PDC: possible causes. Science 262, 825-826 (1993).
91. Nagano, I., Wong, P. C. & Rothstein, J. D. Nitration of glutamate transporters in transgenic mice with a familial amyotrophic lateral sclerosis-linked SOD1 mutation. Ann. Weurol. 40, 542 (1996).
92. Oosthuyse, B. et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Wature Genet. 28, 131-138 (2001).
93. Rabin, B. A. et al. Autosomal dominant juvenile amyotrophic lateral sclerosis. Brain 122, 1539-1550 (1999).
94. Chance, P. F. et al. Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34. Am. J. Hum. Genet. 62, 633-640 (1998).
95. Hentati, A. et al. Linkage of a commoner form of recessive amyotrophic lateral sclerosis to chromosome 15q15-q22 markers. Weurogenetics 2, 55-60 (1998).
96. Hadano, S. et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Wature Genet. 29, 166-173 (2001).
97. Yang, Y. et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Wature Genet. 29, 160-165 (2001).
98. Ince, P. et al. Parvalbumin and calbindin D-28k in the human motor system and in motor neuron disease. Weuropathol. Appl. Weurobiol. 19, 291-299 (1993).
99. Al-Chalabi, A. et al. Recessive amyotrophic lateral sclerosis families with the D90A SOD1 mutation share a common founder: evidence for a linked protective factor. Hum. Mol. Genet. 7, 2045-2050 (1998).
100. Kunst, C. B., Messer, L., Gordon, J., Haines, J. & Patterson, D. Genetic mapping of a mouse modifier gene that can prevent ALS onset. Genomics 70, 181-189 (2000).
101. Kasarkis, E. J. et al. A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Weurology 52, 1427-1433 (1999).
102. Akbar, M. T. et al. Expression of glial glutamate transporters GLT-1 and GLAST is unchanged in the hippocampus in fully kindled rats. Weuroscience 78, 351-359 (1997).
103. Borasio, G. D. et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Weurology 51, 583-586 (1998).
104. Lai, E. C. et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Weurology 49, 1621-1630 (1997).
105. Bensimon, G., Lacomblez, L., Meininger, V. & The ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. W. Engl. J. Med. 330, 585-591 (1994).
106. Lacomblez, L., Bensimon, G., Leigh, P. N., Guillet, P. & Meininger, V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347, 1425-1431 (1996).
107. Klivenyi, P. et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Mature Med. 5, 347-350 (1999).
108. Andreassen, O. A. et al. Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J. Weurochem. 77, 383-390 (2001).
109. Shinder, G. A., Lacourse, M. C., Minotti, S. & Durham, H. D. Mutant Cu/Zn-superoxide dismutase proteins have altered solubility and interact with heat shock/stress proteins in models of amyotrophic lateral sclerosis. J. Biol. Chem. 276, 12791-12796 (2001).
110. Hosler, B. A. et al. Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21 -q22. J. Am. Med. Assoc. 284, 1664-1669 (2000).
111. Siddique, T. et al. X-linked dominant locus for late-onset familial amyotrophic lateral sclerosis. Am. J. Hum. Genet. 63, A308 (1998).
112. Jung, C. et al. Synthetic superoxide dismutase/catalase mimetics reduce oxidative stress and prolong survival in a mouse amyotrophic lateral sclerosis model. Weurosci. Lett. 304, 157-160 (2001).
113. Reinholz, M. M., Merkle, C. M. & Poduslo, J. F. Therapeutic benefits of putrescine-modified catalase in a transgenic mouse model of familial amyotrophic lateral sclerosis. Exp. Weurol. 159, 204-216 (1999).
114. Andreassen, O. A. et al. Effects of an inhibitor of poly(ADP- ribose) polymerase, desmethylselegiline, trientine, and lipoic acid in transgenic ALS mice. Exp. Weurol. 168, 419-424 (2001).
115. Jiang, F., DeSilva, S. & Turnbull, J. Beneficial effect of ginseng root in SOD-1 (G93A) transgenic mice. J. Weurol. Sci. 180, 52-54 (2000).
116. Andreassen, O. A., Dedeoglu, A., Klivenyi, P, Beal, M. F & Bush, A. I. W-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Weuroreport 11, 2491-2493 (2000).
117. Andreassen, O. A. et al. Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP. Exp. Weurol. 167, 189-195 (2001).
118. Trieu, V. N., Liu, R., Liu, X. P. & Uckun, F. M. A specific inhibitor of janus kinase-3 increases survival in a transgenic mouse model of amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 267, 22-25 (2000).
119. Upton-Rice, M. N., Cudkowicz, M. E., Mathew, R. K., Reif, D. & Brown, R. H. Jr. Administration of nitric oxide synthase inhibitors does not alter disease course of amyotrophic lateral sclerosis SOD1 mutant transgenic mice. Ann. Weurol. 45, 413-414 (1999).
120. Nagano, S., Ogawa, Y, Yanagihara, T. & Sakoda, S. Benefit of a combined treatment with trientine and ascorbate in familial amyotrophic lateral sclerosis model mice. Weurosci. Lett. 265, 159-162 (1999).
121. Gurney, M. E. et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Weurol. 39, 147-157 (1996).
122. Dugan, L. L. et al. Carboxyfullerenes as neuroprotective agents. Proc. Watl Acad. Sci. USA 94, 9434-9439 (1997).
123. Desnuelle, C., Dib, M., Garrel, C. & Favier, A. A double-blind, placebo-controlled randomized clinical trial of a-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS Riluzole-Tocopherol Study Group. Amyotroph. Lateral Scler. Other Motor Weuron Disord. 2, 9-18 (2001).
124. Hottinger, A. F., Fine, E. G., Gurney M. E., Zurn, A. D. & Aebischer, P. The copper chelator D-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis. Eur. J. Weurosci. 9, 1548-1551 (1997).
125. Keep, M., Elmer, E., Fong, K S. & Csiszar, K. Intrathecal cyclosporin prolongs survival of late-stage ALS mice. Brain Res. 894, 327-331 (2001).
126. Barneoud, P & Curet, O. Beneficial effects of lysine acetylsalicylate, a soluble salt of aspirin, on motor performance in a transgenic model of amyotrophic lateral sclerosis. Exp. Weurol. 155, 243-251 (1999).
127. Frank, K. M., Coccia, C., Drachman, D. B. & Rothstein, J. D. COX-2 inhibition prolongs survival in a transgenic mouse model of ALS. Soc. Weurosci.Abstr. 27 (in the press).
128. Haverkamp, L. J., Smith, R. G. & Appel, S. H. Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann. Weurol. 36, 253-254 (1994).
129. Appel, S. H. et al. A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis. Arch. Weurol. 45, 381-386 (1988).
130. Mora, J. S. et al. Intrathecal administration of natural human interferon a in amyotrophic lateral sclerosis. Weurology 36, 1137-1140 (1986).
131. Patten, E. Therapeutic plasmapheresis and plasma exchange. Crit. Rev. Clin. Lab. Sci. 23, 147-175 (1986).
132. Harrington, H., Hallett, M. & Tyler, H. R. Ganglioside therapy for amyotrophic lateral sclerosis: a double-blind controlled trial. Weurology 34, 1083-1085 (1984).
133. Bradley, W. G. et al. A double-blind controlled trial of bovine brain gangliosides in amyotrophic lateral sclerosis. Weurology 34, 1079-1082 (1984).
134. Hallett, M., Harrington, H., Tyler, H. R., Flood, T. & Slater, N. Trials of ganglioside therapy for amyotrophic lateral sclerosis and diabetic neuropathy. Adv. Exp. Med. Biol. 174, 575-579 (1984).
135. Bradley, W. G. Double-blind controlled trial of purified brain gangliosides in amyotrophic lateral sclerosis and experience with peripheral neuropathies. Adv. Exp. Med. Biol. 174, 565-573 (1984).
136. Friedlander, R. M., Brown, R. H., Gagliardini, V, Wang, J. & Yuan, J. Inhibition of ICE slows ALS in mice. Wature 388, 31 (1997).
137. Prudlo, J. et al. Motor neuron cell death in a mouse model of FALS is not mediated by the p53 cell survival regulator. Brain Res. 879, 183-187 (2000).
138. Miller, R. G. et al. A clinical trial of verapamil in amyotrophic lateral sclerosis. Muscle Wen/e 19, 511-515 (1996).
139. Miller, R. G. et al. Controlled trial of nimodipine in amyotrophic lateral sclerosis. Weuromuscul. Disord. 6, 101-104 (1996).
140. Slusher, B. S. et al. Naaladase inhibition increases survival and delays clinical symptoms in SOD transgenic model of ALS. Soc. Weurosci. Abstr. 26, 43.10 (2000).
141. Sutherland, M. L., Martinowich, K. & Rothstein, J. D. EAAT2 overexpression plays a neuroprotective role in the SOD1 G93A model of amyotrophic lateral sclerosis. Soc. Weurosci. Abstr. 27, (in the press).
142. Plaitakis, A., Smith, J., Mandeli, J. & Yahr, M. D. Pilot trial of branched-chain amino acids in amyotrophic lateral sclerosis. Lancet 1, 1015-1018 (1988).
143. Mohajeri, M. H., Figlewicz, D. A. & Bohn, M. C. Intramuscular grafts of myoblasts genetically modified to secrete glial cell line-derived neurotrophic factor prevent motoneuron loss and disease progression in a mouse model of familial amyotrophic lateral sclerosis. Hum. Gene Tier. 10, 1853-1866 (1999).
144. Dreibelbis, J. E., Cudkowicz, M. E., Pastuszak, K. A., Smith, E. R. & Brown, R. H. Jr. Intracisternal injection of bone morphogenic protein-7 at time of disease onset did not alter disease course in a transgenic mouse model of amyotrophic lateral sclerosis. Soc. Weurosci.Abstr. 26, 865-4 (2000).
145. Bordet, T. et al. Protective effects of cardiotrophin-1 adenoviral gene transfer on neuromuscular degeneration in transgenic ALS mice. Hum. Mol. Genet. 10, 1925-1933 (2001).
146. Sun, W. & Funakoshi, H. N. T. Hepatocyte growth factor gene transfer improves life span, motor function and motorneuronal death in an ALS transgenic mouse model. Soc. Weurosci. Abstr. 27, (in the press).
147. Munsat, T. L. et al. Intrathecal thyrotropin-releasing hormone does not alter the progressive course of ALS: experience with an intrathecal drug delivery system. Weurology 42, 1049-1053 (1992).
148. Brooks, B. R., Sufit, R. L., Montgomery, G. K., Beaulieu, D. A. & Erickson, L. M. Intravenous thyrotropin- releasing hormone in patients with amyotrophic lateral sclerosis. Dose-response and randomized concurrent placebo-controlled pilot studies. Weurol. Clin. 5, 143-158 (1987).
149. Caroscio, J. T. et al. A double-blind, placebo-controlled trial of TRH in amyotrophic lateral sclerosis. Weurology 36, 141-145 (1986).
150. Trieu, V N. & Uckun, F. M. Genistein is neuroprotective in murine models of familial amyotrophic lateral sclerosis and stroke. Biochem. Biophys. Res. Commun. 258, 685-688 (1999).
151. Norris, F. H., Denys, E. H. & Fallat, R. J. Trial of octacosanol in amyotrophic lateral sclerosis. Weurology 36, 1263-1264 (1986).
152. Munsat, T. L., Easterday, C. S., Levy, S., Wolff, S. M. & Hiatt, R. Amantadine and guanidine are ineffective in ALS. Weurology 31, 1054-1055 (1981).
153. Olarte, M. R., Gersten, J. C., Zabriskie, J. & Rowland, L. P. Transfer factor is ineffective in amyotrophic lateral sclerosis. Ann. Weurol. 5, 385-388 (1979).
154. Olson, W. H., Simons, J. A. & Halaas, G. W. Therapeutic trial of tilorone in ALS: lack of benefit in a double-blind, placebo-controlled study. Weurology 28, 1293-1295 (1978).
155. Fareed, G. C. & Tyler, H. R. The use of isoprinosine in patients with amyotrophic lateral sclerosis. Weurology 21, 937-940 (1971).
156. Ende, N., Weinstein, F, Chen, R. & Ende, M. Human umbilical cord blood effect on sod mice (amyotrophic lateral sclerosis). Life Sci. 67, 53-59 (2000).
157. Maragakis, N. J. et al. Transplanted neural stem cells are capable of engraftment and diffrentiation in transgenic mutant SOD1 mice. Soc. Weurosci.Abstr. 26, 668.3 (2000).